Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche [Seeking Alpha]
Wave Life Sciences Ltd. - Ordinary Shares (WVE)
Last wave life sciences ltd. - ordinary shares earnings: 3/2 06:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.wavelifesciences.com/news-releases?page=1%2c0%2c0%2c0
Company Research
Source: Seeking Alpha
The company faces intense competition from other RNA-based therapeutics companies, such as Alnylam, that have successfully brought treatments to market. Investment recommendation: Hold, due to intense competition, financial sustainability concerns, and current market sentiment. Wave Life Sciences Sails Into Obesity: A New Horizon or a Mirage? Wave Life Sciences NASDAQ: WVE ), an RNA-focused, clinical-stage biotechnology company, is trending after reporting on Wednesday that it is entering the obesity field. Per their report: INHBE lead clinical candidate selected; potential best-in-class treatment for obesity with potent and durable silencing, weight loss with no loss of muscle mass, reduction of visceral fat, and every-six-month or annual subcutaneous dosing; clinical trial initiation expected 1Q 2025. Their clinical candidate is based on years of research into the loss of function (LOF) of the INHBE gene. RNAi-based therapeutics company, Alnylam ALNY discussed the Nature
Show less
Read more
Impact Snapshot
Event Time:
WVE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WVE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WVE alerts
High impacting Wave Life Sciences Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
WVE
News
- Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing [Yahoo! Finance]Yahoo! Finance
- Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA EditingGlobeNewswire
- Cadenza Bio, Inc. Appoints Michael A. Panzara, MD, MPH, to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Wave Life Sciences Ltd. (NASDAQ: WVE) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $17.00 price target on the stock.MarketBeat
- Wave Life Sciences to Present at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
WVE
Earnings
- 3/6/24 - Beat
WVE
Sec Filings
- 4/5/24 - Form 4
- 4/3/24 - Form 144
- 3/6/24 - Form 10-K
- WVE's page on the SEC website